Redefining what’s possible in cystic fibrosis treatment
Our vision is to fully normalize CFTR function
We’re developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function.
DC / IND-Enabling
Excellence together to redefine what is possible for patients